DRW Securities’s Aligos Therapeutics ALGS Stock Holding History

DRW Securities’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,950	Closed	-$111K	–	1244
2025 Q4	$111K	Buy	+11,950	New	+$113K	﹤0.01%	1054

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DRW Securities's ALGS Position: Q1 2026 in Review

DRW Securities sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 11,950 shares — an estimated $111K sold.

DRW Securities first reported a position in ALGS in Q4 2025 and held it in 1 quarter. The position peaked at $111K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

DRW Securities reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 11,950 Aligos Therapeutics shares in Q1 2026, an estimated $111K.
DRW Securities first reported a position in Aligos Therapeutics in Q4 2025 and held it in 1 quarter.
DRW Securities's Aligos Therapeutics position peaked at $111K in Q4 2025.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.